American Journal of Cardiology
Volume 102, Issue 5 , Pages 541-545 , 1 September 2008

A Clinical Risk Score for Prediction of Stent Thrombosis

  • Kenneth W. Baran, MD

      Affiliations

    • St. Paul Heart Clinic, St. Paul, Minnesota
    • Corresponding Author InformationCorresponding author: Tel: 651-292-0616; Fax: 651-726-7258
    • ,
  • John M. Lasala, MD, PhD

      Affiliations

    • Washington University School of Medicine, St. Louis, Missouri
    • ,
  • David A. Cox, MD

      Affiliations

    • Lehigh Valley Heart Specialists, Allentown, Pennsylvania
    • ,
  • Aijun Song, MS

      Affiliations

    • Boston Scientific Corp., Natick, Massachusetts
    • ,
  • Mahesh C. Deshpande, MS, MBA

      Affiliations

    • Boston Scientific Corp., Natick, Massachusetts
    • ,
  • Mary V. Jacoski, MS

      Affiliations

    • Boston Scientific Corp., Natick, Massachusetts
    • ,
  • Stephen R. Mascioli, MD

      Affiliations

    • Boston Scientific Corp., Natick, Massachusetts
    • ,
  • ARRIVE Investigators

Received 29 February 2008 ,Revised 23 April 2008 ,Accepted 23 April 2008.

References 

  1. Gottschall CAM, Quadros AS, Sarmento-Leite R. Acute coronary syndromes: predictive score for target vessel revascularization after bare metal coronary stenting. J Invasive Cardiol. 2006;18:22–26
  2. Singh M, Lennon RJ, Holmes DR, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:387–393
  3. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  4. Waksman R, Buch AN, Torguson R, Xue Z, Smith K, Javaid A, et al. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry). Am J Cardiol. 2007;100:45–51
  5. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher Registry. Circulation. 2006;113:1434–1441
  6. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, et al Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  7. Lasala JM, Cox DA, Dobies D, Muhlestein JB, Katopodis JN, Revtyak G, Baim DS; for the ARRIVE 1 Participating Physicians. Usage patterns and 2-year outcomes with the Taxus Express stent: results of the U.S. ARRIVE 1 registry. Catheter Cardiovasc Interv. Epub ahead of print, April 21, 2008. doi:10.1002/ccd.21618.
  8. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001–2009
  9. Hioki Y, Aoki N, Kawano K, Homori M, Hasumura Y, Yasumura T, et al. Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur Heart J. 2001;22:56–61
  10. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients; the EVASTENT matched-cohort registry. J Am Coll Cardiol. 2007;50:501–508
  11. Park D-W, Park S-W, Park K-H, Lee B-K, Kim Y-H, Lee CW, et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352–356
  12. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  13. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  14. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803–2809
  15. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late Angiographic Stent Thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  16. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention (A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines). Circulation. 2008;117:261–295
  17. Lasala JM, Cox DA, Mascioli SR, Baim DS ARRIVE Participating Physicians. Predictors for stent thrombosis in real-world use of the Taxus Express2 paclitaxel-eluting stent: insights from the 7000-patient ARRIVE program. In: Presented at Transcatheter Cardiovascular Therapeutics. Washington, DC, October 22. 2007;http://www.aievolution.com/tct0701/index.cfm?do=abs.pubSearchOptionsTCT no. 536. Accessed June 6, 2008

 This work was supported by Boston Scientific Corp., Natick, Massachusetts.

PII: S0002-9149(08)00747-9

doi: 10.1016/j.amjcard.2008.04.068

American Journal of Cardiology
Volume 102, Issue 5 , Pages 541-545 , 1 September 2008

Article Tools

* Image Usage & Resolution